At 15: 00 p.m. on April 16, a warm spring day with pleasant breeze, many guests gathered in Room 501, Block A2, Tianfu Life Science Park, Chengdu, chatting and laughing. With soft music and fragrant champagne, the "Open Visit Day" activity of Chengdu Shinesta Medicine (Chengdu) Co., Ltd. was held in the newly renovated, concise and bright central activity area of the company. After two years of efforts, Shinesta Medicine (Chengdu) Co., Ltd.. officially settled in Tianfu Life Science Park.

       At the invitation and strong support of Chengdu High-tech Zone Management Committee, Shinesta Medicine (Chengdu) Co., Ltd. was established in Chengdu in June 2019. It was founded by domestic authorities and experts in the field of innovative drug research and development. The company is positioned to provide CRO services on innovative drug R&D strategy formulation, China-US double application, innovative drug FIH/phase I trials, phase II-IV clinical trials. The development goal of the company is to keep a foothold in Chengdu & face the world, and become an international clinical CRO enterprise.

       The event saw a number of heavyweight guests from the government, hospitals and enterprises: Director Huang Wei and Division Chief Li Wenjin of Biological Industry Development Bureau of High-tech Zone; Miao Jia, Director of Phase I Laboratory of West China Hospital of Sichuan University, Yu Qin, Director of GCP Center of West China Second University Hospital of Sichuan University, He Lin, Director of GCP Center of Sichuan Provincial People's Hospital, and Yong Xiaolan, Director of Pharmacy Department of Chengdu Xinhua Hospital; Wang Li, Chairman of WestChina-Frontier, Huang Jinkun, Chairman of Xiling Lab, Liu Xiaoyu, Chairman of FANXI Biopharma, Yuan Chenguang, President of Hyperway Pharmaceuticals, Shi Lingyang, Chairman of Haitong Pharmaceutical, Chen Hong, deputy general manager of Easton Biopharmaceuticals, and representatives from CHIPSCREEN, Haisco, Jiabo Yaoyin and other enterprises.

Figure Group Photo of Guests from Government, Hospitals and Enterprises Attending Shinesta Medicine's Open Visit Day

       After the start of the event, Dr. Wu Yonggang, General Manager of Shinesta Medicine, delivered a welcome speech, explaining the original intention of Shinesta Medicine to serve its hometown based on Chengdu, as well as his sincere welcome and heartfelt thanks to all guests. Huang Wei, Director of Biological Industry Development Bureau of Chengdu High-tech Zone, reviewed the growth process of Shinesta Medicine, fully affirmed the company's achievements in the early stage, and put forward ardent expectations and important instructions for the later development. Zhu Xi, Deputy General Manager of Shinesta Medicine, introduced the establishment background, founding team, business service scope and achievements of Shinesta Medicine to the guests from various aspects.

Figure Huang Wei, Director of Biological Industry Development Bureau of Chengdu High-tech Zone, Making Important Speech

       Shinesta Medicine (Chengdu) Co., Ltd. signed a strategic cooperation agreement with WestChina-Frontier Pharmatech Co., Ltd. and Chengdu Haifeng Pharmaceutical Technology Co., Ltd. to provide the "one-stop" service option of preclinical-clinical-registration for new drug R&D customers in Southwest China.

Figure Shinesta Medicine Signing Strategic Cooperation Agreement with WestChina-Frontier and Haifeng Biopharma

       In the second session of the event, Dr. Shen Huaqiong, CEO of I-Mab Biopharma, was specially invited to share ideas on international research and development of innovative drugs and the practical experience on China-US double application. The response was enthusiastic, and guests from hospitals and enterprises actively expressed their views and participated in the discussion.

Figure Dr. Shen Huaqiong, CEO of I-Mab Biopharma, Sharng Ideas on International Research and Development of Innovative Drugs and Practical Experience on China-US Double Application

       So far, there is still a lack of professional clinical research service providers in Southwest China. The Management Committee of the High-tech Zone, hospital representatives and entrepreneurs have put forward ardent expectations for professional clinical research services based in the Southwest China. Shinesta Medicine (Chengdu) Co., Ltd. will bear the expectations and support of all parties, deepen its research in the field of clinical research, and help the development of innovative drugs in Southwest China.

Figure Dr. Miao Jia, Director of Phase I Laboratory of West China Hospital, Sharing Her Experience and Expectations of Clinical R&D

Figure Dr. Wang Li, Chairman of WestChina-Frontier, a Strategic Partner of Shinesta Medicine, Shared Her Experience in New Drug R&D Services and the Outlook for Strategic Cooperation with Shinesta Medicine

Figure Yuan Chenguang, President of Hyperway Pharmaceuticals Sharing His Understanding of Clinical R&D and Expressing His Congratulations to Shinesta Medicine

Figure Guests Discussing on New Drug R&D in Activity Room of Shinesta Medicine

       The atmosphere of this Open Visit Day was relaxed and pleasant, which was highly praised by the participating guests. In the future, Shinesta will organize more events and exchanges on drug clinical R&D to provide high-quality clinical R&D services for new drug R&D enterprises in Southwest China.